Barclays’s Transmedics TMDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.8M | Buy |
237,615
+47,037
| +25% | +$3.98M | ﹤0.01% | 1253 |
|
|
2026
Q1 | $18.9M | Sell |
190,578
-9,127
| -5% | -$1.19M | ﹤0.01% | 1126 |
|
|
2025
Q4 | $24.3M | Sell |
199,705
-2,153
| -1% | -$270K | 0.01% | 1143 |
|
|
2025
Q3 | $22.6M | Buy |
201,858
+16,434
| +9% | +$1.92M | ﹤0.01% | 1168 |
|
|
2025
Q2 | $24.8M | Sell |
185,424
-27,074
| -13% | -$2.97M | 0.01% | 1008 |
|
|
2025
Q1 | $14.3M | Sell |
212,498
-13,905
| -6% | -$956K | ﹤0.01% | 1196 |
|
|
2024
Q4 | $14.1M | Buy |
226,403
+35,603
| +19% | +$3.31M | ﹤0.01% | 1315 |
|
|
2024
Q3 | $30M | Buy |
190,800
+84,858
| +80% | +$13.1M | 0.01% | 873 |
|
|
2024
Q2 | $16M | Sell |
105,942
-91,649
| -46% | -$11M | ﹤0.01% | 1016 |
|
|
2024
Q1 | $14.6M | Sell |
197,591
-8,490
| -4% | -$700K | 0.01% | 1159 |
|
|
2023
Q4 | $16.3M | Buy |
206,081
+23,472
| +13% | +$1.42M | 0.01% | 1163 |
|
|
2023
Q3 | $10M | Buy |
182,609
+31,092
| +21% | +$2.24M | 0.01% | 993 |
|
|
2023
Q2 | $12.7M | Buy |
151,517
+135,977
| +875% | +$10.4M | 0.01% | 892 |
|
|
2023
Q1 | $1.18M | Buy |
15,540
+7,346
| +90% | +$508K | ﹤0.01% | 2606 |
|
|
2022
Q4 | $506K | Buy |
8,194
+6,900
| +533% | +$367K | ﹤0.01% | 3306 |
|
|
2022
Q3 | $54K | Sell |
1,294
-56
| -4% | -$2.44K | ﹤0.01% | 3758 |
|
|
2022
Q2 | $42K | Sell |
1,350
-2,972
| -69% | -$79.3K | ﹤0.01% | 4102 |
|
|
2022
Q1 | $116K | Sell |
4,322
-27,137
| -86% | -$486K | ﹤0.01% | 3715 |
|
|
2021
Q4 | $603K | Buy |
31,459
+20,866
| +197% | +$523K | ﹤0.01% | 3121 |
|
|
2021
Q3 | $350K | Buy |
10,593
+7,260
| +218% | +$222K | ﹤0.01% | 3357 |
|
|
2021
Q2 | $110K | Sell |
3,333
-17,686
| -84% | -$490K | ﹤0.01% | 3809 |
|
|
2021
Q1 | $872K | Buy |
21,019
+11,482
| +120% | +$353K | ﹤0.01% | 2861 |
|
|
2020
Q4 | $189K | Sell |
9,537
-1,963
| -17% | -$29K | ﹤0.01% | 3789 |
|
|
2020
Q3 | $158K | Sell |
11,500
-866
| -7% | -$14.8K | ﹤0.01% | 3998 |
|
|
2020
Q2 | $223K | Buy |
12,366
+7,634
| +161% | +$119K | ﹤0.01% | 3984 |
|
|
2020
Q1 | $57K | Sell |
4,732
-9,511
| -67% | -$159K | ﹤0.01% | 5148 |
|
|
2019
Q4 | $271K | Buy |
14,243
+10,980
| +337% | +$202K | ﹤0.01% | 4800 |
|
|
2019
Q3 | $77K | Sell |
3,263
-6,825
| -68% | -$164K | ﹤0.01% | 5669 |
|
|
2019
Q2 | $292K | Buy |
+10,088
| New | +$275K | ﹤0.01% | 4782 |
|
Other funds holding TMDX
Barclays's TMDX Position: Q2 2026 in Review
Barclays increased its Transmedics (TMDX) stake by 25% in Q2 2026, buying an estimated $3.98M and bringing the position to 237,615 shares worth $15.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1253.
Barclays first reported a position in TMDX in Q2 2019 and has held it in 29 quarters since. The position peaked at $30M in Q3 2024. 376 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.
- Barclays held 237,615 shares of Transmedics worth $15.8M as of Q2 2026.
- Barclays bought 47,037 Transmedics shares in Q2 2026, an estimated $3.98M.
- Transmedics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1253 holding.
- Barclays first reported a position in Transmedics in Q2 2019 and has held it in 29 quarters since.
- Barclays's Transmedics position peaked at $30M in Q3 2024.
- 376 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.